整合素β3在三阴性乳腺癌中的表达及其与预后的关系  

Expression of Integrin β3 in Triple Negative Breast Cancer and Its Prognostic Significance

作　　者：李聪[1] 张悦[1] 任延律[1] 黄元夕[1] 李志高[1] 庞达[1] 程绍强[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院,黑龙江哈尔滨150081

出　　处：《肿瘤学杂志》2016年第12期1037-1041,共5页Journal of Chinese Oncology

基　　金：黑龙江省自然科学基金项目(H2015051)

摘　　要：[目的]探讨整合素β3在三阴性乳腺癌中的临床意义。[方法]免疫组织化学染色法检测98例三阴性乳腺癌组织中整合素β3的表达情况。[结果]在三阴性乳腺癌患者中整合素β3表达与患者的绝经状态及淋巴结转移状态密切相关（P〈0.05）。整合素β3阳性的三阴性乳腺癌患者的5年无病生存时间及乳腺癌特异性生存时间均显著差于整合素β3阴性者。Cox多因素分析显示整合素β3是三阴性乳腺癌预后不良的独立危险因素（HR=1.910,95%CI：1.069－3.413;P=0.029）。[结论 ]整合素β3可作为判断三阴性乳腺癌预后的重要指标及潜在的治疗靶点。[Objective] To explore the clinical significance of integrin β3expression in triple negative breast cancer（TNBC）. [Methods] The expression of integrin β3 was detected in 98 patients with TNBC by immunohistochemical staining. [Results] Integrin β3 was significantly associated with menopausal status and lymph node status（P〈0.05）. Patients with positive integrin β3 expression had worse 5-year disease-free survival and breast cancer-specific survival than patients with negative expression. Cox multivariate analysis showed that integrin β3 was an independent unfavorable prognostic factor for patients with TNBC（HR =1.910,95% CI：1.069 ~3.413;P =0.029）.[Conclusion] Integrin β3 can be used as the prognostic marker and potential therapy target for TNBC.

关 键 词：三阴性乳腺癌 整合素Β3 预后 

分 类 号：R737.9[医药卫生—肿瘤]